Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of ALKS 3831 in Acute Exacerbation of Schizophrenia
2015-003373-15Phase 3Completed
- Sponsor
- Alkermes
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olanzapine + samidorphan in schizophrenia (2 arms), sponsored by Alkermes. Primary endpoint: Change from baseline in PANSS total score at Week 4. Started Feb 2016; status: completed.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2015-003373-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003373-15.